Wall Street's Short Sizzle: November Picks Revealed!

Wall Street's Fresh Holy Trinity of "These Shorts Are Getting Cooked" – November 13, 2026 Edition

Back at it, you beautiful degenerates. Markets remain the same glorious shitshow—AI hype juicing the Nasdaq while the Dow sits on its ass like a retiree in Boca, and crude oil bounces around like a drunk on a pogo stick. I scoured the freshest short-interest scans and signals (including live borrow vibes and volatility overlays from recent settlement data) for three brand-new names where the bears are piled higher than a Wall Street bonus pool on a bad year, and the bulls are yelling “squeeze me harder.” No repeats of the usual suspects like NBIS, CORZ, OKLO, or the prior crypto/AI/biotech/nuclear crew. Just pure, unfiltered fresh meat with serious short pressure and “prove me wrong, bitch” vibes. Here’s today’s unholy trinity.[1]

1. SMR (NuScale Power): The Small Modular Reactor Play That’s Either Powering the AI Data Center Boom or Getting Regulatory Nuked into Oblivion

The Bull Case (Clean Baseload for Hyperscalers, First-Mover Mojo, and Squeeze Juice):
Bulls are creaming over NuScale’s small modular reactor (SMR) tech tailored for data centers and AI power hunger—government approvals, flexible deployment, and massive unmet demand for reliable, carbon-free energy. Any new contracts, regulatory wins, or clean energy rotation could spark a short squeeze (recent scans showing elevated short interest with solid days-to-cover). “We’ve got the tech edge, the AI tailwinds, and the asymmetric upside—watch the shorts get SMR’d when plants go live” is the battle cry.[2]

The Bear Case (Regulatory Doom Loop, No Revenue Scale Yet, and Classic Deep-Tech Cash Inferno):
Reality check: Brutal questions on long regulatory/commercial timelines, lack of binding power purchase agreements despite pipelines, ongoing high burn with dilution risks from raises, and first-of-a-kind execution uncertainties. High short pressure reflects the market’s “yeah, right” on flawless scaling in a heavily regulated, capital-intensive space. One delay, funding crunch, or hype fade and it’s pain. NuScale? More like “No Scale—shorts are harvesting the downside.”

My First-Principles Breakdown:
Strip it down: Nuclear plays win on validated tech with regulatory traction, diversified or de-risked pipelines, resilient capital access across cycles, and actual build/operational discipline—not just “nuclear renaissance” buzz. SMR has real advanced reactor IP and approvals, but “success” requires surviving burn and dilution, proving commercial contracts at scale, and navigating regs without endless equity raises. Shorts correctly price in the binary and timeline risks; bulls correctly price in the energy demand asymmetry if deployments hit. High-vol deep-tech energy bet—entertaining as hell, size accordingly or cry into your empty reactor core later.

2. NNE (Nano Nuclear Energy): The Micro-Reactor Upstart That’s Either Miniaturizing the AI Energy Revolution or Getting Vaporized by Hype and Execution Risks

The Bull Case (Portable Power for Remote/AI Needs, Tech Novelty, and Squeeze Fuel):
Bulls are pumped on Nano Nuclear’s micro-reactor concepts for distributed power, including data centers and off-grid applications—IP edge, government interest, and the broader nuclear/AI energy narrative. Revenue potential from licensing or deployments, plus any sector rotation, could trigger a short squeeze (recent data flagging high short interest). “We’ve got the micro edge, the AI tailwinds, and the hype—watch the shorts get NNE’d when reactors ship” is the mantra.[2]

The Bear Case (Speculative Tech Binary, No Commercial Product Yet, and Classic Volatile Deep-Tech Hell):
Reality bites: Brutal risks from early-stage tech with long development timelines, lack of proven deployments, cash burn/dilution pressures, and competition in the crowded nuclear space. Recent short interest spikes amid execution fears and earnings reactions underscore the skepticism. One missed milestone, funding issue, or sector rotation away and it’s pain. Nano Nuclear? More like “No Nuclear—shorts are harvesting the downside.”

My First-Principles Breakdown:
Fundamentally, micro-nuclear plays win on defensible IP, scalable manufacturing or licensing paths, resilient balance sheets across cycles, and actual tech validation—not just “tiny reactor gold rush” buzz. NNE has real conceptual novelty and interest, but “breakout” requires flawless execution on development without endless capital raises or tech setbacks. Shorts correctly flag the timeline and commercialization risks; bulls correctly flag the power density upside if it works. High-vol speculative bet—entertaining as hell, size accordingly or cry into your empty micro-core later.

3. CCCC (C4 Therapeutics): The Targeted Protein Degradation Biotech That’s Either Degrading Cancer Cells into Profits or Getting Clinical Trial Wrecked and Diluted to Death

The Bull Case (Novel Platform Promise, Pipeline Catalysts, and Squeeze Juice):
Bulls are fired up on C4’s targeted protein degradation tech for oncology and other diseases—innovative approach beyond traditional inhibitors, advancing pipeline, and potential big-pharma partnerships or data readouts. Any positive trial results, deals, or biotech rotation could spark a short squeeze (recent scans showing elevated short interest). “We’ve got the platform edge, the unmet need, and the asymmetric upside—watch the shorts get CCCC’d when degradation delivers” is the hype.[3]

The Bear Case (Clinical Binary, High Burn, and Classic Biotech Execution Inferno):
Reality check: Brutal questions on clinical trial risks and timelines, lack of approved products or meaningful revenue, ongoing cash burn with dilution risks from raises, and competition in the crowded degradation space. High short pressure reflects the market’s “yeah, right” on flawless execution in a high-failure-rate industry. One missed endpoint, safety issue, or funding crunch and it’s pain. C4 Therapeutics? More like “See You Later—shorts are harvesting the downside.”

My First-Principles Breakdown:
Biotech plays win on differentiated mechanisms with de-risked validation, diversified pipelines, resilient capital access across cycles, and actual clinical/operational discipline—not just “next big platform” buzz. CCCC has real novel tech and pipeline momentum, but “success” requires surviving burn and dilution, proving clinical wins at scale, and navigating regs/partnerships without endless equity raises. Shorts correctly price in the binary and failure risks; bulls correctly price in the platform asymmetry if data hits. High-vol biotech bet—entertaining as hell, size accordingly or cry into your empty trial folder later.

Bottom Line (No Crystal Ball, Just Brutal Logic):
These three capture the current divided vibe: advanced nuclear scaling gamble, micro-nuclear speculative play, and targeted degradation biotech binary. The common thread? Sky-high skepticism via short signals and volatility, but real catalysts that could flip the script. Markets adore punishing uncertainty—and these names are marinated in it. Laugh at the chaos, size positions like your rent depends on it (or don’t), and remember: this is entertainment with numbers. Your move, degenerates.

Sources for the terminally curious (verify this shit yourself): Recent short-interest trackers and signals (e.g., Tapeboard most-shorted screens, ChartMill, MetaCap, AltIndex) highlighting elevated pressure in SMR, NNE, and CCCC; company updates, sector debates, and filings on nuclear/AI energy and biotech platforms. Always do your own digging—these are snapshots of a deranged market. Trade responsibly, or at least don’t cry when it goes tits up.